Mikhail Blagosklonny is an oncologist. He studies aging and cancer. Mikhail works at the Roswell Park Cancer Institute, New York where he serves as the Oncology professor. Mikhail has worked in the oncology field as a scientist for many years. He has been able to acquire massive skills and experience. Mikhail attended the First Pavlov State Medical University, St. Petersburg where he got his MD in Internal Medicine and also a Ph.D. in Experimental Medicine and Cardiology. Mikhail Blagosklonny became the associate professor of Medicine working for the New York Medical College, Valhalla in 2002. Mikhail later went on to serve at the Ordway Research Institute, Albany, NY where he was a senior scientist.
The Roswell Park Cancer Institute appointed Mikhail Blagosklonny as the oncology professor in 2009. The research interests for Mikhail include cancer and targeted cancer therapies protecting regular cells from damage, underlying aging mechanisms (also known as Biogerontology), and anti-aging drugs. Mikhail is famous for the popular cancer drug known as Rapamycin. He proposed the use of the drug in the treatment of life extension. Mikhail Blagosklonny is referred as one of the most committed advocates for Rapamycin in the longevity research. Read more on Impact Journals.
Mikhail is an author. He has written several articles about oncology. He works at Oncotarget and Aging Cell Cycle as the Editor-in-chief. Mikhail serves as the associate editor at the Cancer Biology and Therapy. Mikhail is also a member of the Cell Death and Differentiation’s editorial board. Oncotarget is a peer-review journal. It has registered a tremendous growth and success under the leadership of Mikhail. Mikhail Blagosklonny has been able to publish more than 270 papers in journals with more than twenty-five thousand citations. This has given him an h-index of 83.
Mikhail’s research mostly includes ontogenesis, signal transduction, drug resistance on normal cells, tumor suppressors, cell cycle, mitosis, anticancer therapeutics, and apoptosis. Mikhail writes about chemotherapeutic engineering and cell psychotherapy. He has earned a reputation as a passionate scientist in the field of oncology. Mikhail serves as the associate editor at PLOS ONE. This is an American Journal of Pathology and International Journal of Cancer. View Mikhail’s profile on Loop